241 related articles for article (PubMed ID: 10636147)
1. Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS.
Kracke A; von Wussow P; Al-Masri AN; Dalley G; Windhagen A; Heidenreich F
Neurology; 2000 Jan; 54(1):193-9. PubMed ID: 10636147
[TBL] [Abstract][Full Text] [Related]
2. Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis.
Kivisäkk P; Alm GV; Fredrikson S; Link H
Eur J Neurol; 2000 Jan; 7(1):27-34. PubMed ID: 10809912
[TBL] [Abstract][Full Text] [Related]
3. RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon-beta-1b.
Iarlori C; Reale M; Lugaresi A; De Luca G; Bonanni L; Di Iorio A; Feliciani C; Conti P; Gambi D
J Neuroimmunol; 2000 Jul; 107(1):100-7. PubMed ID: 10808056
[TBL] [Abstract][Full Text] [Related]
4. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre.
Río J; Tintoré M; Nos C; Téllez N; Galán I; Montalban X
J Neurol; 2005 Jul; 252(7):795-800. PubMed ID: 15772741
[TBL] [Abstract][Full Text] [Related]
5. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
[TBL] [Abstract][Full Text] [Related]
6. Interferon beta-1b treatment in patients with relapsing--remitting multiple sclerosis under a standardized protocol in Spain.
Arbizu T; Alvarez-Cermeño JC; Decap G; Fernández O; Uría DF; García Merino A; Izquierdo G; Montalbán X
Acta Neurol Scand; 2000 Oct; 102(4):209-17. PubMed ID: 11071104
[TBL] [Abstract][Full Text] [Related]
7. Plasma ubiquitin-proteasome system profile in patients with multiple sclerosis: correlation with clinical features, neuroimaging, and treatment with interferon-beta-1b.
Minagar A; Ma W; Zhang X; Wang X; Zhang K; Alexander JS; Gonzalez-Toledo E; Albitar M
Neurol Res; 2012 Jul; 34(6):611-8. PubMed ID: 22709658
[TBL] [Abstract][Full Text] [Related]
8. Clinical and laboratory study of pro-inflammatory and antiinflammatory cytokines in women with multiple sclerosis.
Trenova AG; Manova MG; Kostadinova II; Murdjeva MA; Hristova DR; Vasileva TV; Zahariev ZI
Folia Med (Plovdiv); 2011; 53(2):29-35. PubMed ID: 21797104
[TBL] [Abstract][Full Text] [Related]
9. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454
[TBL] [Abstract][Full Text] [Related]
10. A comparative study of the relative bioavailability of different interferon beta preparations.
Deisenhammer F; Mayringer I; Harvey J; Dilitz E; Gasse T; Stadlbauer D; Reindl M; Berger T
Neurology; 2000 Jun; 54(11):2055-60. PubMed ID: 10851362
[TBL] [Abstract][Full Text] [Related]
11. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
Nikfar S; Rahimi R; Abdollahi M
Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
[TBL] [Abstract][Full Text] [Related]
12. Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients.
Vallittu AM; Halminen M; Peltoniemi J; Ilonen J; Julkunen I; Salmi A; Erälinna JP;
Neurology; 2002 Jun; 58(12):1786-90. PubMed ID: 12084878
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of a 'refrigeration-free' formulation of interferon beta-1b--results of a double-blind, multicentre, comparative study in patients with relapsing-remitting or secondary progressive multiple sclerosis.
Baum K;
J Int Med Res; 2006; 34(1):1-12. PubMed ID: 16604818
[TBL] [Abstract][Full Text] [Related]
14. Anticytokine antibodies in beta interferon-treated MS patients and the need for testing: plight of the practicing neurologist.
Pachner AR
Neurology; 1997 Sep; 49(3):647-50. PubMed ID: 9305316
[No Abstract] [Full Text] [Related]
15. What is new in the treatment of multiple sclerosis?
Weinstock-Guttman B; Jacobs LD
Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
[TBL] [Abstract][Full Text] [Related]
16. The clinical impact of interferon beta antibodies in relapsing-remitting MS.
Perini P; Calabrese M; Biasi G; Gallo P
J Neurol; 2004 Mar; 251(3):305-9. PubMed ID: 15015010
[TBL] [Abstract][Full Text] [Related]
17. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
[TBL] [Abstract][Full Text] [Related]
18. Systemic IFN-beta treatment induces apoptosis of peripheral immune cells in MS patients.
Gniadek P; Aktas O; Wandinger KP; Bellmann-Strobl J; Wengert O; Weber A; von Wussow P; Obert HJ; Zipp F
J Neuroimmunol; 2003 Apr; 137(1-2):187-96. PubMed ID: 12667663
[TBL] [Abstract][Full Text] [Related]
19. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.
Koch-Henriksen N; Sørensen PS; Christensen T; Frederiksen J; Ravnborg M; Jensen K; Heltberg A; Kristensen O; Stenager E; Petersen T; Hansen T;
Neurology; 2006 Apr; 66(7):1056-60. PubMed ID: 16510769
[TBL] [Abstract][Full Text] [Related]
20. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b.
Antonelli G; Simeoni E; Bagnato F; Pozzilli C; Turriziani O; Tesoro R; Di Marco P; Gasperini C; Fieschi C; Dianzani F
J Neurol Sci; 1999 Oct; 168(2):131-6. PubMed ID: 10526196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
